SALSALATE SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H9O5.Na
Molecular Weight	280.208
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

[Na+].OC1=CC=CC=C1C(=O)OC2=CC=CC=C2C([O-])=O

InChI

InChIKey=JOCPDKGMOXSKRO-UHFFFAOYSA-M

InChI=1S/C14H10O5.Na/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17;/h1-8,15H,(H,16,17);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C14H9O5
Molecular Weight	257.2183
Charge	-1
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
prostaglandin biosynthetic process 23	Inhibitor 8,504

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 320	Palliative	Approved 8,583	DISALCID
Osteoarthritis 157	Palliative	Approved 8,583	DISALCID
Type 2 diabetes mellitus 262	Primary	Phase III 665	Unknown

C_max

Value	Dose	Analyte	Population
45 μg/mL	1500 mg single, oral	SALSALATE plasma	Homo sapiens
17 μg/mL	1500 mg single, oral	SALSALATE plasma	Homo sapiens
88 μg/mL	1500 mg single, oral	SALICYLIC ACID plasma	Homo sapiens
97 μg/mL	1500 mg single, oral	SALICYLIC ACID plasma	Homo sapiens
21.1 μg/mL	1000 mg single, oral	SALSALATE plasma	Homo sapiens
54.4 μg/mL	1000 mg single, oral	SALICYLIC ACID plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
101 μg × h/mL	1500 mg single, oral	SALSALATE plasma	Homo sapiens
50 μg × h/mL	1500 mg single, oral	SALSALATE plasma	Homo sapiens
847 μg × h/mL	1500 mg single, oral	SALICYLIC ACID plasma	Homo sapiens
1301 μg × h/mL	1500 mg single, oral	SALICYLIC ACID plasma	Homo sapiens
50 μg × h/mL	1000 mg single, oral	SALSALATE plasma	Homo sapiens
498 μg × h/mL	1000 mg single, oral	SALICYLIC ACID plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
1.2 h	1500 mg single, oral	SALSALATE plasma	Homo sapiens
2.1 h	1500 mg single, oral	SALSALATE plasma	Homo sapiens
3.8 h	1500 mg single, oral	SALICYLIC ACID plasma	Homo sapiens
8.1 h	1500 mg single, oral	SALICYLIC ACID plasma	Homo sapiens
1.1 h	1000 mg single, oral	SALSALATE plasma	Homo sapiens
3.5 h	1000 mg single, oral	SALICYLIC ACID plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
5%			SALICYLIC ACID serum	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
1.5 g 3 times / day multiple, oral Higher than recommended	unhealthy, ADULT	Disc. AE: Tinnitus, Headache... Other AEs: Tinnitus...
2 g 2 times / day multiple, oral MTD	unhealthy, ADULT	Disc. AE: Tinnitus...
1.5 g 2 times / day multiple, oral Recommended	unhealthy, ADULT	Disc. AE: Gastro-intestinal disorder NOS, Tinnitus...

Showing 1 to 3 of 3 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Headache	14.3% Disc. AE	1.5 g 3 times / day multiple, oral Higher than recommended	unhealthy, ADULT
Tinnitus	14.3% Disc. AE	1.5 g 3 times / day multiple, oral Higher than recommended	unhealthy, ADULT
Tinnitus	85.7%	1.5 g 3 times / day multiple, oral Higher than recommended	unhealthy, ADULT
Tinnitus	37.5% Disc. AE	2 g 2 times / day multiple, oral MTD	unhealthy, ADULT
Dizziness	1.7% Disc. AE	1.5 g 2 times / day multiple, oral Recommended	unhealthy, ADULT

Showing 1 to 5 of 7 entries

Previous1 2Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2,252 inducer 1,087	inhibitor 2,438	inhibitor 2,507	inhibitor 2,217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 CYP2E1 1,060 BSEP 550 CYP1A2 2,153 CYP2C19 2,057 CYP19A1 429	P-gp 2,052

Drug as perpetrator

Show entries

Target	Modality	Activity
CYP1A2 2,333	inhibitor 4,027	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4,027	no [IC50 >10 uM]
CYP2C19 2,141	inhibitor 4,027	no [IC50 >10 uM]
CYP2C9 2,497	inhibitor 4,027	no [IC50 >10 uM]
CYP2D6 2,546	inhibitor 4,027	no [IC50 >10 uM]

Showing 1 to 5 of 10 entries

Previous1 2Next

Drug as victim

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2,052	substrate 4,014	no

Showing 1 to 1 of 1 entries

Previous1Next

Tox targets

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2,263	inhibitor 2,237

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Modulation of endothelial cell activation in sickle cell disease: a pilot study.	2001 Apr 1	11264155
Lichenoid drug eruption to salsalate.	2001 Oct	11568758
Blood pressure elevation in a patient treated with salsalate.	2002 Apr	11918510
Nonsteroidal antiinflammatory drug starter packs for chronic musculoskeletal pain.	2002 Jul	12126217
Variable effects of nonsteroidal antiinflammatory agents on thyroid test results.	2003 Dec	14671157

Showing 1 to 5 of 32 entries

Previous1 2 3 4 5 6 7Next

Patents

Sample Use Guides

In Vivo Use Guide

The usual dosage is 3000 mg daily, given in divided doses as follows: 1(two doses of two 750 mg tablets; 2) two doses of three 500 mg tablets; or 3) three doses of two 500 mg tablets.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical
Record UNII	06SH0H2G8M
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

SALSALATE SODIUM

Common Name

English

2-HYDROXYBENZOIC ACID 2-CARBOXYPHENYL ESTER SODIUM SALT

Preferred Name

English

SODIUM SALICYLSALICYLATE

Systematic Name

English

BENZOIC ACID, 2-HYDROXY-, 2-CARBOXYPHENYL ESTER, MONOSODIUM SALT

Systematic Name

English

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Code System

Code

Type

Description

FDA UNII

06SH0H2G8M

PRIMARY

PUBCHEM

23662396

PRIMARY

EPA CompTox

DTXSID40178111

PRIMARY

CAS

23520-54-9

PRIMARY

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Related Record

Type

Details


					V9MO595C9I

SALSALATE

PARENT -> SALT/SOLVATE

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					V9MO595C9I

SALSALATE

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator